title: A platform of integrative studies from in vitro to in vivo experiments: towards drug development for ischemic retinopathy.
abstract: Pathologic angiogenesis induced by hypoxia is a hallmark of ischemic retinopathy including diabetic retinopathy and retinopathy of prematurity. These 2 diseases affect substantial number of working population and preterm babies, respectively, resulting in visual deterioration. It is essential for novel therapeutics for ischemic retinopathy to demonstrate the potency in reducing pathologic angiogenesis and the safety without definite toxicity on the retina and the whole body. In this review, we suggest a novel platform of integrative studies from in vitro to in vivo experiments on angiogenesis and toxicity with the aim of accelerating and facilitating the development of novel therapeutic agents for ischemic retinopathy. Robust in vitro and in vivo studies with bridging microfluidic and ex vivo systems help researchers to evaluate the efficacy and anticipate the toxicity of candidate drugs. We hope that novel therapeutic approach based on this platform will be developed in near future and reduce the incidence of vision loss from ischemic retinopathy.
authors: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Department of Ophthalmology, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 110-799, Republic of Korea.
authors: Dong Hyun
authors: DH
authors: Jo
authors: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Department of Ophthalmology, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea.
authors: Jin Hyoung
authors: JH
authors: Kim
authors: Fight against Angiogenesis-Related Blindness (FARB) Laboratory, Clinical Research Institute, Seoul National University Hospital, Department of Ophthalmology, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea; Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul 110-799, Republic of Korea; Department of Ophthalmology, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea; Protein Metabolism Medical Research Center, College of Medicine, Seoul National University, Seoul 110-744, Republic of Korea. Electronic address: steph25@snu.ac.kr.
authors: Jeong Hun
authors: JH
authors: Kim
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007511:Ischemia / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D012164:Retinal Diseases / Q000188:drug therapy*
keywords: Diabetic retinopathy; Drug development; Ischemic retinopathy; Pathologic angiogenesis; Retinopathy of prematurity